Ewa Żurawska-Płaksej, Agnieszka Piwowar, Maria Warwas

Współczesne możliwości wczesnego rozpoznawania i leczenia farmakologicznego choroby niedokrwiennej serca

Contemporary possibilities of early recognition and pharmacological treatment of ischemic heart disease. In the light of still increasing numbers of patients suffer from ischemic heart disease (IHD) and huge costs of hospitalization of patients with symptoms suggestive of acute coronary syndromes, quick and proper identification of cardiac ailment become very important task for novel cardiological diagnosis. Routine measurements of cTnT, CK-MB and Myo is not sufficient enough for early recognition of IHD. Recent investigations have indicated new biomarkers with potential utility in estimating of the degree of disease development and risk of acute cardiac incidents and which could be helpful in undertaking right decisions about therapeutical treatment - farmacological or invasive. Currently, great hopes arise new markers of inflammatory states and plaque destabilization as well as ischemia modified albumin, which is the first marker indicating ischemia before necrosis and helpful in ruling out myocardial infarction. Very important are also new solutions in farmacological therapy such as combination traditional anti-ischemic drugs (nitrates, beta-blockers, calcium blockers) with cytoprotective specimens (trimetazidine). Moreover, the role of angiotensin converting enzyme inhibitors and hypolipemic drugs (eg. statins) in IHD treatment is still considered.